(MENAFN-Pressat) Toronto-based studies report a 90% reduction in viral infectivity in samples from SARS-CoV-2 patients with Ondine’s nasal antimicrobial photodynamic disinfection (aPDT), with 70% of patient samples absolutely inactivated with a 5-minute treatment alone. The nose is the main access site of SARS-CoV-2 and plays a central role in the transmission and severity of the disease.
The Journal of Nature/Scientific Reports an article from the Sunnybrook Research Institute in Toronto reporting that nasal antimicrobial photodynamic disinfection (aPDT) treatment inactivates SARS-CoV-2 well in the noses of COVID-19 patients. [i]
The paper, “Translational Feasibility and Efficacy of Sars-CoV-2 Nasal Photodynamic Disinfection,” reports that 90% of patient samples showed reduced viral infectivity, and 70% showed no detectable viruses after a 5-minute treatment without marriage.
The Canadian study team commented: “These promising effects imply the prospect of photodisinfection as a new tool against COVID-19 and lead to further studies. This treatment, which has been clinically validated in high-risk surgical cases, results in significant relief. “in surgical site infections, it can be vital not only against COVID-19, but also against other communicable viral and bacterial diseases.
The study was led by an organization of leading researchers from the Sunnybrook Research Institute, the University of Toronto Health Network, the University of Toronto School of Medicine, the Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, and the Roy Romanow Provincial Laboratory at the University of Toronto. Saskatchewan Health Authority, Regina, Canada. The researchers used Ondine Biomedical’s Steriwave™ nasal photodenfection as part of the study.
Carolyn Cross, CHIEF Executive of Ondine, said: “Nasal photodeninfection provides healthcare systems with a simple, fast and cost-effective remedy to protect against COVID-19, as well as bacterial cofactors that can complicate infections. We are very pleased that this study has been conducted through Dr. Sunnybrook’s Cari Whyne confirms that photodeninfection is effective against SARS-CoV-2 transmission and further suggests that photodisinfection might be effective against other viruses. Since the cure for nasal photodisfection is already being implemented in Canadian hospitals to save healthcare-related infections, we look to the future to continue our work to demonstrate the efficacy of photodeninfection against new viral strains and other emerging threats.
Dr Nicolas Loebel, President and Chief Technology Officer of Ondine, said: “This new knowledge from Sunnybrook demonstrates that it is conceivable to reduce or eliminate the infectivity of upper respiratory viruses with just a few minutes of painless nasal photodisinfection. We believe it is now incredibly important to collaborate with government agencies, fitness systems, and local hospitals to ensure that all patients and healthcare personnel have access to this indisputable and effective technique, in addition to vaccination, PPE, and other criteria of care.
“As we approach autumn, other people will spend more time indoors and transmission of new variants of COVID-19 will inevitably build up. New variants of Omicron such as BA. 2. 12. 1, BA. 4 and BA. 5 are known as “super diffusers” because they can evade antibodies caused by the initial SARS2 infection and also by all existing vaccines. This escape allows for immediate transmission between patients, and while patients are in the poor health they used to have, we believe the possibility of overburdening healthcare facilities this fall and winter is very real. More importantly, the co-infection between those new strains of SARS-CoV-2 and other viruses (e. g. , influenza, monkeypox, etc. ), as well as bacteria can accumulate strains in a patient’s immune formula and cause even more mutations as co-infected pathogens share genomic data with each other.
[ME]
MENFN31082022004644010603ID1104786869
Keywords
Feedback
Category
Date